[
    "hane (0.072 ml; 0.0009mol) and anhydrous K2CO3(0.104 g; 0.0007mol) were added successively to a solution of 5, 7-bis (benzyloxy) -2- (3, 4-bis (benzyloxy) phenyl) -3-hydroxy-4H-chromen-4-one 7(0.2 g; 0.0003mol) in anhydrous DMF (2.14 ml). The reaction mixture was stirred at a temperature of 65 \u2103 for 12 hours. Upon completion, the reaction was partitioned between water (10ml) and EtOAc/DCM (1/1; 30 ml). The organic phase was washed with saturated aqueous NaCl and the aqueous phase was extracted with 10ml EtOAc/DCM (1/1). The combined organic phases were dried over anhydrous sodium sulfate, the solvent was removed under reduced pressure and purified by flash column chromatography (SiO 2; EtOAc/n-hexane 25%) to give the residue as a yellow solid (290 mg). Product 8a was isolated as a white solid (120mg, 60%).</p></p><sup>1</sup>H NMR(400MHz,CDCl<sub>3</sub>):7.83(d,2H),7.68(dd,1H),7.61(d,2H),7.54-7.27(m\uff1b19H),7.02(d,1H),6.53(d,1H),6.45(d,1H),5.24(d,6H),5.09(s,1H),4.06(q,2H),1.26(t,3H)\uff1b</p><sup>13</sup>C NMR(100MHz,CDCl<sub>3</sub>):173.95,162.66,159.77,158.65,152.70,150.65,148.27,140.23,137.05,136.77,136.40,135.71,128.74,128.57,128.53,128.41,127.95,127.87,127.61,127.58,127.31,127.19,126.66,124.15,122.20,115.26,113.81,98.01,93.86,71.43,70.93,70.79,70.45,68.15,15.60\u3002</p>Synthesis example of 5, 7-bis (benzyloxy) -2- (3, 4-bis (benzyloxy) phenyl) -3-hexyloxy-4H-chromen-4-one 8 b:</p>hexyl bromide (0.084 ml; 0.0006mol) and anhydrous K<sub>2</sub>CO<sub>3</sub>(0.104 g; 0.0007mol) and KI (0.015 g; 0.00009mol) were added successively to a solution of 5, 7-bis (benzyloxy) -2- (3, 4-bis (benzyloxy) phenyl) -3-hydroxy-4H-benzopyran-4-one 7(0.2 g; 0.0003mol) in anhydrous DMF (2.14 ml). The reaction mixture was stirred at a temperature of 65 \u2103 for 12 hours. Upon completion, the mixture was partitioned between water (10ml) and EtOAc/DCM (1/1; 30 ml). The organic phase was washed with saturated aqueous NaCl and the aqueous phase was extracted with 10ml EtOAc/DCM (1/1). The combined organic phases were washed with anhydrous Na<sub>2</sub>SO<sub>4</sub>Dried and the solvent removed under reduced pressure. Purification by cold precipitation from EtOAc/hexanes solution gave a yellow oily residue (173 mg). The white solid product corresponding to 8b was separated from the liquid by centrifugation and the traces of solvent were removed under reduced pressure.</p>White solid 8b (67.5 mg; 30%).</p></p><sup>1</sup>H NMR(400MHz,CDCl<sub>3</sub>):7.82(d,2H,J\uff1d1.8Hz),7.68(dd,1H,J<sub>1</sub>\uff1d8.6Hz\uff1bJ<sub>2</sub>\uff1d1.8,Hz),7.62(d,2H,J\uff1d7.6Hz,CH<sub>2</sub>Ph),7.55-7.27(m,18H,CH<sub>2</sub>Ph),7.02(d,1H,J\uff1d8.6Hz),6.53(d,1H,J\uff1d2.0Hz),6.45(d,1H,J\uff1d2.0Hz),4.02(t,2H,J\uff1d7.1Hz),1.56-1.53(m,2H),1.40-1.20(m,6H),0.87(t,3H,J\uff1d7.1Hz)\u3002</p><sup>13</sup>C NMR(100MHz,CDCl<sub>3</sub>):173.82,162.56,159.68,152.53,150.60,148.24,140.43,136.73,136.40,128.66,128.45,127.87,127.80,127.53,127.28,127.12,126.59,124.07,122.28,115.23,113.72,110.01,97.96,93.79,72.67,71.40,70.85,70.68,70.37,31.59,30.08,25.52,22.54,13.98\u3002</p>Synthesis example of 5, 7-bis (benzyloxy) -2- (3, 4-bis (benzyloxy) phenyl) -3-hexadecyloxy-4H-benzopyran-4-one 8 c:</p>hexyl decyl bromide (0.2 g; 0.0007mol), anhydrous K<sub>2</sub>CO<sub>3</sub>(0.121 g; 0.0009mol) and KI (0.017 g; 0.0001mol) were added in succession to a solution of 5, 7-bis (benzyloxy) -2- (3, 4-bis (benzyloxy) phenyl) -3-hydroxy-4H-benzopyran-4-one 7(0.2 g; 0.0003mol) in anhydrous DMF (3 ml). The reaction mixture was stirred at a temperature of 65 \u2103 for 2 hours. Upon completion, the reaction mixture was partitioned between water (10ml) and EtOAc/DCM (1/1; 30 ml). The organic phase was washed with saturated aqueous NaCl and the aqueous phase was extracted with 10ml EtOAc/DCM (1/1). The combined organic phases were washed with anhydrous Na<sub>2</sub>SO<sub>4</sub>Dried and the solvent removed under reduced pressure. By flash column chromatography (SiO)<sub>2</sub>(ii) a EtOAc/n-hexane 15%) the obtained residue (490mg) was purified and the desired product 8c was isolated as a white solid (250mg, 73.5%).</p></p><sup>1</sup>H NMR(400MHz,CDCl<sub>3</sub>):7.79(d,1H,J\uff1d1.8Hz),7.66(dd,1H,J<sub>1</sub>\uff1d8.6Hz,J<sub>2</sub>\uff1d1.8Hz),7.59(d,2H,J\uff1d7.4Hz,CH<sub>2</sub>Ph),7.53-7.28(m,18H,CH<sub>2</sub>Ph),7.01(d,1H,J\uff1d8.6Hz),6.52(d,1H,J\uff1d1.8Hz),6.44(d,1H,J\uff1d1.8Hz),5.254(s,3H,CH<sub>2</sub>Ph),5.248(s,3H,CH<sub>2</sub>Ph),5.23(s,3H,CH<sub>2</sub>Ph),5.09(s,3H,CH<sub>2</sub>Ph),3.98(t,2H,J\uff1d7.1Hz),1.67(t,2H),1.30-1.19(m,29H),0.38(q,3H)\uff1b</p><sup>13</sup>C NMR(100MHz,CDCl<sub>3</sub>):173.76,162.54,159.65,158.52,152.44,150.60,148.25,137.00,136.71,136.40,135.70,128.61,128.45,128.40,128.26,127.83,127.48,127.26,127.10,126.57,122.23,115.22,113.71,109.99,97.91,93.79,72.65,71.37,70.84,70.65,70.32,31.82,30.13,29.61,29.55,29.42,29.26,25.87,22.59,14.02\u3002</p>Example of synthesis of compound 11 a.</p>Ethyl 4-bromobutyrate (218. mu.l; 1.508mmol) and anhydrous K<sub>2</sub>CO<sub>3</sub>(250 mg; 1.810mmol) and KI (36 mg; 0.226mmol) are added successively to a solution of 5, 7-bis (benzyloxy) -2- (3, 4-bis (benzyloxy) phenyl) -3-hydroxy-4H-chromen-4-one 7(0.5 g; 0.754mmol) in anhydrous DMF (4 ml). The reaction mixture was stirred at a temperature of 65 \u2103 for 12 hours. Upon completion, the reaction was partitioned between water (20ml) and EtOAc (20 ml). The organic phase was washed with saturated aqueous NaCl and the aqueous phase was extracted with 10ml EtOAc. The combined organic phases were dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. By flash column chromatography (SiO)<sub>2</sub>(ii) a EtOAc/n-hexane 25%) purified the residue. Product 11a was isolated as a white oil (440mg, 75%).</p></p><sup>1</sup>H NMR(400MHz,DMSO-d6):7.76(s,1H),7.66(d,1H,J\uff1d8.0Hz),7.61(d,2H,J\uff1d7.9Hz),7.49(m,6H),7.38(m,12H),7.36(d,1H,J\uff1d4.8Hz),6.91(d,1H,J\uff1d2.0Hz),6.69(d,1H,J\uff1d2.0Hz),5.23(m,8H),4.01(q,2H,J\uff1d6.8Hz),3.91(t,2H,J\uff1d6.4Hz),2.38(t,2H,J\uff1d7.2Hz),1.85(t,2H,J\uff1d6.8Hz),1.12(t,3H,J\uff1d7.2Hz)\u3002</p><sup>13</sup>C NMR(100MHz,DMSO-d6):173.4,173.1,163.5,160.0,159.0,152.8,151.2,148.7,140.4,138.0,137.8,137.7,137.0,129.5,129.4,129.1,129.0,128.9,128.5,128.4,127.9,124.0,122.9,115.1,114.7,109.9,98.7,95.1,71.6,71.4,71.0,70.9,30.9,25.9,15.0\u3002</p>Example of synthesis of compound 11 b.</p>2- [2- (Boc-amino) ethoxy]Ethyl bromide (404 mg; 1.508mmol), anhydrous K<sub>2</sub>CO<sub>3</sub>(250 mg; 1.810mmol) and KI (36 mg; 0.226mmol) were added successively to 5, 7-bis (benzyloxy) -2- (3, 4-bis (benzyloxy)Yl) phenyl) -3-hydroxy-4H-chromen-4-one 7(500 mg; 0.754mmol) in anhydrous DMF (4 ml). The reaction mixture was stirred at a temperature of 65 \u2103 for 12 hours. Upon completion, the mixture was partitioned between water (10ml) and EtOAc (20 ml). The organic phase was washed with saturated aqueous NaCl and the aqueous phase was extracted with EtOAc (20 mL). The combined organic phases were washed with anhydrous Na<sub>2</sub>SO<sub>4</sub>Dried and the solvent removed under reduced pressure. By flash column chromatography (SiO)<sub>2</sub>(ii) a EtOAc/n-hexane 25%) the residue obtained was purified as a yellow oil. Product 11b was isolated as a white oil (460mg, 72%).</p></p>1H NMR(400MHz,DMSO-d6):7.83(bs,1H),7.63(d,1H,J\uff1d4.0Hz),7.46-7.18(m,21H),6.95(d,1H,J\uff1d2.0Hz),6.76(bt,1H,J\uff1d8.0Hz),6.70(d,1H,J\uff1d2.0Hz),5.25(m,8H),4.12(m,2H),3.60(m,2H),3.32(m,2H),3.03(m,2H),1.35(s,9H)\u3002</p>13C NMR(100MHz,DMSO-d6):173.2,163.6,159.0,156.5,152.5,151.2,148.6,140.3,138.1,137.8,137.7,137.0,129.5,129.4,129.3,129.2,129.0,128.9,128.8,128.6,128.5,127.8,123.9,123.3,115.1,114.6,109.8,98.7,95.1,78.6,71.6,71.4,71.0,70.9,70.3,70.0,29.1\u3002</p>Example of synthesis of compound 11 c.</p>2- [2- (benzyloxy) ethoxy]Ethyl bromide (390 mg; 1.508mmol), anhydrous K<sub>2</sub>CO<sub>3</sub>(250 mg; 1.810mmol) and KI (36 mg; 0.226mmol) were added successively to a solution of 5, 7-bis (benzyloxy) -2- (3, 4-bis (benzyloxy) phenyl) -3-hydroxy-4H-chromen-4-one 7(0.5 g; 0.754mmol) in dry DCM (4 ml). The reaction mixture was stirred at a temperature of 65 \u2103 for 12 hours. Upon completion, the reaction was partitioned between water (20ml) and EtOAc (20 ml). The organic phase was washed with saturated aqueous NaCl and the aqueous phase was extracted with EtOAc (10 mL). The combined organic phases were washed with anhydrous Na<sub>2</sub>SO<sub>4</sub>Dried and the solvent removed under reduced pressure. By flash column chromatography (SiO)<sub>2</sub>(ii) a EtOAc/n-hexane 25%) the obtained residue was purified as a light yellow solid. The product 11a was isolated as a white oil(539mg\uff0c85\uff05)\u3002</p></p><sup>1</sup>H NMR(400MHz,DMSO-d6):7.63(d,1H,J\uff1d7.6Hz),7.50(d,4H,J\uff1d7.6Hz),7.47-7.28(m,22H),7.20(d,1H,J\uff1d8.4Hz),6.93(d,1H,J\uff1d1.2Hz),6.72(d,1H,J\uff1d1.2Hz),5.25(m,6H),5.04(m,2H),4.95(m,2H)\u3002</p><sup>13</sup>C NMR(100MHz,DMSO-d6):172.9,163.2,159.6,158.6,158.4,152.6,150.5,148.0,139.6,137.5,136.7,128.8,128.5,128.4,128.3,128.2,128.1,128.0,127.9,127.3,123.3,122.2,114.6,114.1,109.3,98.3,94.6,73.3,70.6,70.4,70.3,70.2\u3002</p>Example of synthesis of compound 12.</p>An aqueous solution of 2N NaOH (2ml) was added to a solution of 11a (440 mg; 0.567mmol) in ethanol (6 ml). The reaction mixture was stirred at room temperature for 12 hours. After completion, an aqueous solution of 2N HCl (-2.5ml) was added to the reaction mixtur",
    "was added under magnetic stirring and an argon atmosphere, and after about 30 minutes HOBt (214 mg; 1.58mmol) was added to a solution of palmitic acid (372 mg; 1.45mmol) in anhydrous DMF (2 ml). The reaction mixture thus obtained was stirred for about thirty minutes and then added dropwise by syringe over 5 minutes to a solution of dopamine HCl (30; 250 mg; 1.32mmol) and DIPEA (1.38 ml; 7.9mmol) in anhydrous DMF (10ml) maintained at 0 deg.C in an ice bath.</p>After the addition was complete, the reaction mixture was allowed to slowly warm to room temperature, then stirred under an argon atmosphere for a further 24 hours, then diluted with AcOEt (30ml), followed by H<sub>2</sub>O (2X 30ml) and saturated NaCl solution (20 ml).</p>The organic phase is passed through anhydrous Na<sub>2</sub>SO<sub>4</sub>Drying, filtration, and concentration to dryness in vacuo afforded the crude product, which was purified by flash column chromatography (SiO)<sub>2</sub>EtOAc/hexanes 30-45%) to give intermediate 31 as a white solid (190mg, 37%).</p></p>1H NMR(400MHz,CD3OD):6.67(d,1H,J\uff1d7.6Hz),6.64(d,1H,J\uff1d2.0Hz),6.51(dd,1H,J1\uff1d7.6Hz,J2\uff1d2.0Hz),3.33(t,2H,J\uff1d7.2Hz),2.62(t,2H,J\uff1d7.2Hz),2.14(t,2H,J\uff1d7.6Hz),1.62-1.51(m,2H),1.37-1.22(m,24H),0.90(t,3H,J\uff1d6.8Hz)\uff1b</p>13C NMR(100MHz,CD3OD):178.3,146.3,144.8,132.0,121.0,116.8,116.3,42.2,37.2,36.0,33.1,30.79,30.76,30.6,30.5,30.4,30.3,27.1,23.7,14.4\u3002</p>Example of synthesis of intermediate 33.</p>Under argon atmosphere, adding K<sub>2</sub>CO<sub>3</sub>(230mg) and KI (43mg) were added successively to a solution of amide 31(170 mg; 0.43mmol) and ethyl 4-bromobutyrate (32) (319 mg; 1.91mmol) in anhydrous DMF (10 ml). The reaction thus obtained was magnetically stirred for 24H, then diluted with EtOAc (40mL) and washed with H<sub>2</sub>O (2X 30ml) and a saturated aqueous solution (20ml) of NaCl. The final organic phase was treated with anhydrous Na<sub>2</sub>SO<sub>4</sub>Drying, filtration and concentration to dryness in vacuo gave the crude product from which intermediate 33(192mg, 72%) was obtained as a white solid after purification by flash column chromatography.</p></p>1H NMR(400MHz,CDCl3):6.81(d,1H,J\uff1d5.6Hz),6.75-6.65(m,2H),5.47(bt,1H),4.13(q,4H,J\uff1d7.2Hz),4.013(t,2H,J\uff1d6.0Hz),4.007(t,2H,J\uff1d6.0Hz),4.04-3.98(m,4H),3.51-3.42(m,2H),2.72(t,2H,J\uff1d6.8Hz),2.53(t,4H,J\uff1d7.6Hz),2.16-2.06(m,6H),1.64-1.53(m,2H),1.34-1.19(m,30H),0.87(t,3H,J\uff1d7.2Hz)\uff1b13C NMR(100MHz CDCl3):173.22,173.19,173.10,149.0,147.5,132.1,121.3,114.9,114.5,68.3,68.1,60.4,40.5,36.8,35.2,30.70,30.68,29.7,29.62,29.59,29.5,29.34,29.32,29.29,25.7,24.73,24.70,22.7,14.2,14.1\u3002</p>Synthetic examples of intermediate 34</p>NaOH (66mg) was added to ester 33(58 mg; 0.095mmol) in THF/MeOH/H<sub>2</sub>O-2/2/1 (5ml) solution: the reaction thus obtained was stirred for 18 hours and then carefully adjusted to a pH of about 5 by the continuous addition of a small amount of 2N HCl (780. mu.l total). The reaction was then diluted with AcOEt (10ml) and H<sub>2</sub>O (2X 6ml) and saturated aqueous NaC",
    "lly by crystal violet method. The synthetic trimer compounds (compound 22a and compound 36) used at concentrations of 30 \u03bc M and 100 \u03bc M inhibited the growth of HCT116 and A375 cells. Ctr, control (treated with vehicle). 22a, compound 22 a; 36, compound 36. By student t-test, p &lt;0.05 compared to control (figure 16).</p>The synthetic flavone derivatives do not interfere with normal human cell proliferation. Proliferation of human skin fibroblasts (WS1) was studied with crystal violet and a spectrophotometer. Quercetin (Que), its synthetic derivative (compound 2) and Apigenin (API) were examined at the indicated concentrations. Apigenin significantly inhibited the proliferation of normal human skin cells, while quercetin and compound 2 did not interfere with their growth. Ctr, control (treated with vehicle). By student t-test, p &lt;0.05 compared to control; p &lt;0.005 (fig. 17).</p>The synthesized flavone derivative selectively induces tumor cell apoptosis. The percentage of cells initiating the cell death program (apoptosis) was quantified by the acridine orange/ethidium bromide method using a fluorescence microscope and Image-J. All synthetic quercetin derivatives (compound 2, compound 5, compound 4, compound 3 and compound 1) induced apoptosis (at 2 hours) in both human colon (HCT116) and skin (melanoma, a375) tumor cell lines, but not in normal cells (human skin fibroblasts, WS 1). The following concentrations of substance (relative to the respective antiproliferative IC50) were used, Compound 2, 50. mu.M (HCT116) or 40. mu.M (A375, WS 1); compound 5, 40 \u03bc M; compound 4, 40 \u03bc M; compound 3, 60 \u03bc M; compound 1, 60. mu.M (HCT116) or 80. mu.M (A375, WS 1). Ctr, control (treated with vehicle). P &lt;0.05 by two-way ANOVA assay compared to control; p &lt; 0.01; p &lt;0.005 and p &lt;0.001 (fig. 18).</p>SynthesizedFlavone derivatives can terminate the cell cycle of melanoma. Evolution of human melanoma cells (a375) throughout the cell cycle was quantified by using the Propidium Iodide (PI) method and a cytofluorimeter. Quercetin (quee) and its synthetic derivatives (compound 1, compound 2, compound 3, compound 4 and compound 5) were used as the respective antiproliferative IC 50. With the exception of compound 3, all compounds studied significantly terminated tumor cells in S and/or G2. Ctr, control (treated with vehicle). H<sub>2</sub>O<sub>2</sub>Hydrogen peroxide (positive control; 200. mu.M). By student's t-test, comparison with control,. alpha.p&lt;0.05\uff1b**\uff0cp&lt;0.01\uff1b***\uff0cp&lt;0.001 (fig. 19).</p>The synthetic flavone derivatives can terminate the cell cycle of colorectal cancer. Evolution of human colon cancer cells (HCT116) throughout the cell cycle was quantified by using the Propidium Iodide (PI) method and a cytofluorimeter. Quercetin (quee) and its synthetic derivatives (compound 1, compound 2, compound 3, compound 4 and compound 5) were used as the respective antiproliferative IC 50. Compounds 1, 3 and 4 significantly terminated tumor cells in S. Ctr, control (treated with vehicle). H<sub>2</sub>O<sub>2</sub>Hydrogen peroxide (positive control; 200. mu.M). By student's t-test, comparison with control,. alpha.p&lt;0.05\uff1b**\uff0cp&lt;0.01\uff1b***\uff0cp&lt;0.001 (fig. 20).</p>The effect of compound 1 on tumor cell cycle is mediated in part by ROS. The cell cycle of human colon cancer (HCT116) and melanoma (a375) cells was examined using the propidium iodide method and cytofluorimeter. The active oxygen (ROS) scavenger, N-acetylcysteine (NAC; 10mM), at least partially prevented compound 1 (used with its antiproliferative IC50) induced effects on the cell cycle in HCT116 (left) and A375 (right) cells. Ctr, control (treated with vehicle). By student's t-test, p &lt;0.05 compared to the respective control (compound 1 for compound 1+ NAC); p &lt; 0.01; p &lt;0.001 (fig. 21).</p>The synthetic flavone derivatives cause an increase in intracellular ROS levels in colorectal cancer. Intracellular Reactive Oxygen Species (ROS) levels were quantified 2 hours after treatment of human colon cancer cells (HCT116) with a fluorescent DCFH2-DA probe. Measurement of fluorescence with a spectrophotometerOptical data, and expressed in arbitrary units (A.U.). Quercetin (QUE) and its synthetic derivatives (Compound 1, Compound 2, Compound 3, Compound 4, Compound 5 and Compound 19b) were used as the respective antiproliferative IC 50. Quercetin had no effect, while compound 1, compound 2, compound 3 and compound 19b significantly increased ROS levels in HCT116 cells (left panel). The effect of compound 1 was blocked by pretreatment with ROS scavenger N-acetyl-L-cysteine (NAC; 10mM) (right panel). H<sub>2</sub>O<sub>2</sub>Hydrogen peroxide (positive control; 500. mu.M). Ctr, control (treated with vehicle). By one-way ANOVA test,. beta.p compared to control&lt;0.05\uff1b**\uff0cp&lt;0.01\uff1b***\uff0cp&lt;0.001 (fig. 22).</p>The table below is divided into two parts, which show the inhibitory concentration (expressed in \u03bc M) representing 50% of the maximal antiproliferative effect (IC50) for each human malignant cell line (line 1, starting from column 2) tested for each compound corresponding to the invention (the numbering of which is shown in column 1 on the left). Cell proliferation was quantified by crystal violet method, spectrophotometry.</p></p></p></p></p></p>Legend: CRC, colorectal cancer; LC, lung cancer; SCC, squamous cell carcinoma; PCC, pancreatic cancer cells; RCC, renal cell carcinoma; PC, prostate cancer; BC, bladder cancer; BRC, breast cancer; HNC, head and neck cancer; HCC, hepatocellular carcinoma; OCC, ovarian cell carcinoma; n.d., not determined.</p>"
]